AJANTPHARM:NSE Ajanta Pharma Limited

INR 2,193.50 -29.55 -1.329255
Icon

Ajanta Pharma Limited (AJANTPHARM:NSE) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 2,193.50

-29.55 (-1.33)%

INR 274.24B

0.26M

N/A

N/A

Icon

AJANTPHARM:NSE

Ajanta Pharma Limited (INR)
COMMON STOCK | NSE
INR 2,193.50
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

INR 274.24B

N/A

INR 2,193.50

Ajanta Pharma Limited (AJANTPHARM:NSE) Stock Forecast

INR 2,070.00
(-5.63%)

Based on the Ajanta Pharma Limited stock forecast from 1 analysts, the average analyst target price for Ajanta Pharma Limited is INR 2,070.00 over the next 12 months. Ajanta Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ajanta Pharma Limited is Bullish , which is based on 12 positive signals and 5 negative signals. At the last closing, Ajanta Pharma Limited’s stock price was INR 2,193.50. Ajanta Pharma Limited’s stock price has changed by +5.35% over the past week, +3.34% over the past month and +89.03% over the last year.

No recent analyst target price found for Ajanta Pharma Limited
No recent average analyst rating found for Ajanta Pharma Limited

Company Overview Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as antimalarial, cardiology, op...Read More

Ajanta House, Mumbai, India, 400067

7,713

March

INR

India

Adjusted Closing Price for Ajanta Pharma Limited (AJANTPHARM:NSE)

Loading...

Unadjusted Closing Price for Ajanta Pharma Limited (AJANTPHARM:NSE)

Loading...

Share Trading Volume for Ajanta Pharma Limited Shares

Loading...

Compare Performance of Ajanta Pharma Limited Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AJANTPHARM:NSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ajanta Pharma Limited (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE
Sun Pharmaceutical Industries .. +6.05 (+0.38%) INR3,736.24B 41.91 27.03

ETFs Containing AJANTPHARM

Symbol Name AJANTPHARM's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Ajanta Pharma Limited (AJANTPHARM:NSE) Stock

Based on ratings from 1 analysts Ajanta Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bullish . The stock has 1 buy, sell and hold ratings.

AJANTPHARM:NSE stock's dividend yield is 1.67%. Our analysis grades AJANTPHARM:NSE stock's dividend yield at A. This means that AJANTPHARM:NSE stock's dividend yield is above 95% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this AJANTPHARM:NSE may be a good dividend stock for its sector.

Based on targets from 1 analysts, the average taret price for AJANTPHARM:NSE is INR 2,070.00 over the next 12 months. The maximum analyst target price is INR 2070 while the minimum anlayst target price is INR 2070.

AJANTPHARM:NSE stock's Price/Earning ratio is 37.34. Our analysis grades AJANTPHARM:NSE stock's Price / Earning ratio at F. This means that AJANTPHARM:NSE stock's Price/Earning ratio is above 51% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange. Based on this AJANTPHARM:NSE may be a overvalued for its sector.

The last closing price of AJANTPHARM:NSE's stock was INR 2,193.50.

The most recent market capitalization for AJANTPHARM:NSE is INR 274.24B.

Based on targets from 1 analysts, the average taret price for AJANTPHARM:NSE is projected at INR 2,070.00 over the next 12 months. This means that AJANTPHARM:NSE's stock price may go down by -5.63% over the next 12 months.

We can't find any ETFs which contains Ajanta Pharma Limited's stock.

As per our most recent records Ajanta Pharma Limited has 7,713 Employees.

Ajanta Pharma Limited's registered address is Ajanta House, Mumbai, India, 400067. You can get more information about it from Ajanta Pharma Limited's website at https://www.ajantapharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...